FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models
Lakins, Matthew A, Koers, Alexander, Giambalvo, Raffaella, Munoz-Olaya, Jose, Hughes, Robert, Goodman, Emma, Marshall, Sylwia, Wollerton, Francisca, Batey, Sarah, Gliddon, Daniel, Tuna, Mihriban, Brewis, Neil
Published in Clinical cancer research (01.08.2020)
Published in Clinical cancer research (01.08.2020)
Get full text
Journal Article
IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
Imianowski, Charlotte J, Kuo, Paula, Whiteside, Sarah K, von Linde, Teresa, Wesolowski, Alexander J, Conti, Alberto G, Evans, Alexander C, Baird, Tarrion, Morris, Benjamin I, Fletcher, Nicole E, Yang, Jie, Poon, Edmund, Lakins, Matthew A, Yamamoto, Masahiro, Brewis, Neil, Morrow, Michelle, Roychoudhuri, Rahul
Published in Cancer research communications (01.08.2024)
Published in Cancer research communications (01.08.2024)
Get full text
Journal Article
Abstract 1864: FS222, a tetravalent bispecific antibody targeting CD137 and PD-L1, is designed for optimal CD137 interactions resulting in potent T cell activation without toxicity
Lakins, Matthew A., Munoz-Olaya, Jose, Veyssier, Christel, Jones, Daniel, Goodman, Emma, Kaka, Quincy, Ofoedu, Jennifer, Hughes, Robert, Gliddon, Daniel, Morrow, Michelle, Brewis, Neil
Published in Cancer research (Chicago, Ill.) (01.07.2021)
Published in Cancer research (Chicago, Ill.) (01.07.2021)
Get full text
Journal Article
Abstract 4547: Clustering CD137 via cell-expressed PD-L1 crosslinking avoided Fc-mediated agonism and resulted in safe and potent conditional lymphocyte activation
Lakins, Matthew A., Koers, Alexander, Giambalvo, Raffaella, Hughes, Robert, Marshall, Sylwia, Wydro, Mateusz, Gradinaru, Cristian, Batey, Sarah, Gliddon, Daniel, Morrow, Michelle, Brewis, Neil
Published in Cancer research (Chicago, Ill.) (15.08.2020)
Published in Cancer research (Chicago, Ill.) (15.08.2020)
Get full text
Journal Article
Abstract 1540: FS222 mAb2, a bispecific conditional agonist antibody targeting CD137 and PD-L1, induces potent lymphocyte activation and has a favorable safety profile
Lakins, Matthew A., Koers, Alexander, Olaya, Jose Munoz, Giambalvo, Raffaella, Jones, Daniel, Pechouckova, Sarka, Goodman, Emma, Marshall, Sylwia, Wydro, Mateusz, Gradinaru, Cristian, Wollerton, Francisca, Batey, Sarah, Gliddon, Daniel, Davies, Michael, Morrow, Michelle, Tuna, Mihriban, Brewis, Neil
Published in Cancer research (Chicago, Ill.) (01.07.2019)
Published in Cancer research (Chicago, Ill.) (01.07.2019)
Get full text
Journal Article
CD137 binding molecules
PECHOUCKOVA, SARKA, MUNOZ-OLAYA, JOSE, TUNA, MIHRIBAN, LAKINS, MATTHEW
Year of Publication 01.06.2020
Get full text
Year of Publication 01.06.2020
Patent
Antibody molecules
WYDRO, MATEUSZ, SURADE, SACHIN, WOLLERTON, FRANCISCA, DYSON, MICHAEL, LAKINS, MATTHEW
Year of Publication 16.03.2020
Get full text
Year of Publication 16.03.2020
Patent
ANTIBODY MOLECULES THAT BIND PD-L1 AND CD137
MUNOZ-OLAYA JOSE, WOLLERTON FRANCISCA, BATEY SARAH, KOERS ALEXANDER, TUNA MIHRIBAN, LAKINS MATTHEW
Year of Publication 26.02.2021
Get full text
Year of Publication 26.02.2021
Patent
Antibody molecules that bind PD-L1 and CD137
MUNOZ-OLAYA, JOSE, BATEY, SARAH, WOLLERTON, FRANCISCA, TUNA, MIHRIBAN, KOERS, ALEXANDER, LAKINS, MATTHEW
Year of Publication 01.02.2020
Get full text
Year of Publication 01.02.2020
Patent
PD-L1 및 CD137에 결합하는 항체 분자
MUNOZ OLAYA JOSE, WOLLERTON FRANCISCA, BATEY SARAH, KOERS ALEXANDER, TUNA MIHRIBAN, LAKINS MATTHEW
Year of Publication 18.03.2021
Get full text
Year of Publication 18.03.2021
Patent